Shots:

• The collaboration will combine Iktos’ generative modeling AI technology with SRI’s SynFini synthetic chemistry platform to develop optimized compound & to facilitate the identification of drug therapies treating multiple viruses- including influenza and COVID-19
• Iktos’AI technology is based on deep generative models that speed up the drug discovery process by automatically designing virtual novel molecules having desirable characteristics of a novel drug therapies
• SRI’s SynFini platform is designed to accelerate discovery and development by automating the design- RSO and production of target molecules. The collaboration demonstrates a new paradigm in rapid discovery against pharmaceutical targets

Click here ­to­ read full press release/ article | Ref: SRI | Image: Iktos